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Inconsistent reports on the therapeutic efficacy of increasing synaptic glycine 
concentration have raised doubt as to the benefit of N-methyl-D-aspartate 
receptor (NMDAr) mediated treatments for schizophrenia. Categorising 
individuals based on broad diagnostic criteria does not appear to adequately 
identify individuals who will benefit from such treatments. Mismatch negativity 
(MMN) may be a suitable biomarker of NMDAr function, to help clarify the 
neurobiological relationship between pharmacological intervention and clinical 
treatment efficacy. MMN is an auditory event-related potential elicited following 
the presentation of a deviant stimulus, when it violates an established sequence 
stored in echoic memory. MMN is a robust deficit in schizophrenia and is 
categorised as a physiological element in the Cognitive Systems domain of the 
Research Domain Criteria framework. However, few studies have examined direct 
pharmacological modulation of MMN in schizophrenia patients. The aim of this 
thesis was to determine the nature of the relationship between MMN and NMDAr 
function, to inform the relative utility of MMN as a biomarker of NMDAr-mediated 
improvements in clinical symptoms in schizophrenia. To achieve this aim, three 
separate empirical studies were performed.  
Study one aimed to determine the nature of the relationship between 
regular cannabis exposure and MMN in otherwise healthy subjects. A cross-
sectional comparison between regular cannabis users and controls was used to 
infer the effects of regular cannabis exposure on endocannabinoid-mediated 




overall sample of regular users and smaller duration MMN amplitude was linearly 
associated with more prolonged and heavier cannabis exposure. These findings 
suggest regular cannabis use alters cannabinoid receptor type-I (CB1) mediated 
inhibition of NMDArs in auditory cortical networks important for MMN 
generation. Further, they suggest regular use alters neurobiological function in 
target pathways of NMDAr-mediated treatments. This is problematic when 
interpreting MMN deficits as pathophysiological correlates of core phenotypes 
and may confound NMDAr-mediated treatment efficacy in schizophrenia.  
Study two aimed to determine whether acute glycine administration and 
adjunct glycine treatment increases MMN generation in chronic schizophrenia 
patients. In a randomised, double-blind, placebo-controlled, between-group trial, 
acute administration of low-dose glycine (0.2g/kg) increased MMN amplitude 
compared to placebo. Smaller duration MMN amplitude at baseline was linearly 
associated with greater severity of negative symptoms and predicted, at trend 
level, the degree of negative symptom improvement following 6-weeks of glycine 
treatment (incremented to 0.6g/kg/day). These findings support the view that 
NMDAr hypofunction contributes to robust MMN deficits observed in 
schizophrenia and demonstrates that MMN is a sensitive index of NMDAr 
hypofunction related to the pathophysiology of negative symptoms. Further, 
these findings support the utility of MMN to stratify neurobiological functioning 
of NMDArs and index change in neuronal function following target engagement of 
NMDAr-mediated treatments.  
 Study three aimed to determine the dose-response relationship between 
vi 
 
glycine and MMN, in a randomised, double-blind, placebo-controlled, crossover 
trial. In an independent sample of healthy controls, this study observed an 
Inverted-U dose-response relationship between glycine dose and MMN 
amplitude. High-dose glycine (0.8g/kg) reduced MMN amplitude compared to 
low- and medium-doses (0.2g/kg and 0.4g/kg, respectively), but did not differ from 
placebo. Smaller baseline MMN amplitude was associated with greater increases 
in MMN following low-dose glycine, suggesting that increasing synaptic glycine 
concentration is more beneficial in the context of NMDAr remediation. These 
findings support MMN as a sensitive biomarker indexing change in NMDAr 
function and may help to inform mechanisms of clinical treatment efficacy 
following increased synaptic glycine concentrations.   
 Findings in this thesis support the utility of MMN to index NMDAr function 
and change in neuronal signalling following target engagement of NMDAr-
mediated treatments. Alterations in MMN generation in regular cannabis users 
suggest MMN is sensitive to long-term plasticity changes in auditory-cortical 
networks. The efficacy of glycine to improve NMDAr neurotransmission in this 
thesis (indexed by MMN) appears to be mediated by NMDAr function prior to 
glycine administration and glycine dose amount. These findings support the 
potential for MMN to identify conditions for optimal treatment efficacy. Future 
studies confirming the presence of an Inverted-U dose-response relationship 
between MMN and other NMDAr agents, such as glycine reuptake inhibitors, may 
assist in tailoring effective treatments and better inform mechanisms of treatment 
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 Chapter Introduction 
Since the development of antipsychotics in the early 1970’s, little progress has 
been made to improve drug efficacy and tolerability in schizophrenia, particularly 
in managing negative symptoms and cognitive deficits. Non-adherence to 
pharmacotherapy is approximately 50% in patients [1] and approximately one 
third do not respond to standard medications [2]. There is currently a lack of 
treatment available to increase motivation, emotional experience, attention, 
thought processes and ability to make judgements. Negative symptoms and 
cognitive deficits are evident in the prodromal phase and are associated with poor 
functional outcome and reduced quality of life in later stages of illness [3]. Greater 
understanding of the mechanisms underlying these core refractory symptoms 
may yield earlier diagnosis and improve symptom management for many patients. 
The following chapter defines schizophrenia as a clinical disorder, before 
reviewing the underlying biological mechanisms of core phenotypes. The primary 
theoretical models of neurotransmitter dysfunction provide a framework to 
discuss the utility of novel N-methyl-D-aspartate receptor (NMDAr) mediated 
treatments, which aim to increase glutamatergic function. Given the role of the 
endocannabinoid system in regulating NMDArs and alterations in this regulatory 
mechanism following repeated cannabis use, the effects of cannabis in relation to 
the pathophysiology of clinical symptoms in schizophrenia are also discussed. The 
chapter concludes by identifying the need for biomarkers in schizophrenia to 
inform mechanisms of treatment heterogeneity following pharmacological 





 Schizophrenia Disorder 
Schizophrenia is a chronic and debilitating mental disorder and is one of the most 
severe in terms of personal suffering and societal burden. The prevalence of 
schizophrenia is approximately 0.30-0.66 cases per 1,000 people, with an 
incidence of 10.2-22.0 new cases per 100,000 people, per year [4, 5]. Typical onset 
occurs in late adolescence or early adulthood, with an initial diagnosis at 
approximately 26 years in males and 30 years in females (for further review, see 
[6]). The behavioural phenotypes of schizophrenia cause great disruptions and 
suffering in the day-to-day life of patients, including reduced functional capacity, 
lower financial stability, increased health care needs, shorter life expectancy [7-9] 
and overall reduced quality of life [3]. The chronic nature of the syndrome also 
generates significant financial burden to the community [10], with an annual cost 
reported in Australia, for example, of approximately $2.6 billion in 2013 [5].  
Two of the most widely used diagnostic criteria for validating the profile of 
schizophrenia are the Diagnostic and Statistical Manual (Version 10; DSM-V) [11], 
and the International Statistical Classification of Disease and Related Health 
Problems (Version 10; ICD-10) [12]. Characteristics of symptoms in the DSM-V are 
divided into two broad symptom domains: positive and negative symptoms. 
Although not included in the diagnostic criteria, neurocognitive decline is also 
considered a core feature of functional disability in schizophrenia [11, 13] and 
characterises the deteriorating nature of the disorder. Due to limited diagnostic 
stability, diverse treatment outcomes and discrete longitudinal course, the 





a dimensional structure, focusing on the stage and severity of presenting 
symptoms [14]. Classifying core phenotypes in a dimensional framework may offer 
greater predictive power for clinical outcomes [15], particularly when 
investigating clinical treatment efficacy of pharmacotherapies or behavioural 
interventions.      
 
1.2.1 Positive Symptoms 
The manifestation of schizophrenia is generally characterised by the onset of 
positive symptoms, which tend to be episodic over time and associated with 
increased risk of self-harm and hospitalisation [16]. Positive symptoms are an 
exacerbation of normal functioning, including delusions, hallucinations, 
disorganised thought and disorganised or catatonic behaviour [17]. Delusions are 
often conceptualised as misinterpretations of other people’s intentions or beliefs 
and are regularly associated with an area of personal reference or significance. 
Patients may experience hallucinations or perceptual abnormalities in a range of 
uni- or multi-modal sensory systems, including olfactory, visual, gustational, and 
somatic [18]. Speech and thought patterns may often become incoherent or 
illogical, where the content of one topic does not contextually link to the next, or 
the original content of the thought is forgotten. The positive symptoms of 
schizophrenia often make it difficult for patients to identify components of their 







1.2.2 Negative Symptoms 
The manifestation of negative symptoms may precede the onset of the first 
psychotic episode and when pronounced during prodromal stages of illness, 
contribute to poorer clinical prognosis and long-term disability [19]. Negative 
symptoms are pervasive throughout the disorder, more stable over time and 
follow a longitudinally independent course when compared to positive symptoms 
[20]. The negative dimension of schizophrenia is characterised by absent or 
diminished emotional and behavioural responses, such as alogia (reduced quality 
or quantity of speech), avolition (reduced ability to initiate and follow through on 
plans), anhedonia (lack of pleasure), flattened affect (expressed as monotonous 
voice tone or immobile facial expressions) and social withdrawal (loss of interest 
in social engagement) [11]. The persistent nature of these symptoms impairs a 
patient’s ability to maintain daily functioning and is associated with cognitive 
decline [21], an arrest in social development and attainment in usual social roles 
[22]. Despite a strong association, the shared variance between negative 
symptoms and cognitive deficits has been shown to be small, suggesting that each 
domain contributes independently to reduced functional outcomes [23]. 
 
1.2.3 Cognitive Deficits 
Neurocognitive decline in schizophrenia represents a moderate-to-severe 
deviation below the norm [24] in areas important for daily functioning, including 
memory, learning, attention, visuo-spatial abilities, language and executive 





to the onset of illness [28] and by the time of onset of the first psychotic episode, 
show stable impairment in several domains [29]. Cognitive deficits are associated 
with reduced ability to perform daily living tasks [30, 31] and reduced measures 
of global functioning and quality of life [3]. These debilitating performance 
outcomes remain consistent throughout chronic stages of illness in most patients 
[29]. Behavioural deficits may be indicative of abnormal neuronal development, 
aberrant neuroplasticity, structural and functional alterations [32], or 
unexpressed genetic components [33-36]. Conceptualising schizophrenia as a 
syndrome of cognitive dysfunction remains a core focus of clinical research, in an 
attempt to clarify the underlying mechanisms that give rise to and maintain these 
disabling features of the disorder.   
 
 Pathophysiology of Schizophrenia  
Advances in molecular biology, genetics and imaging techniques provide evidence 
of alterations in several neurotransmitter systems, including dopamine, 
glutamate, gamma-aminobutyric acid (GABA) and serotonin, which link abnormal 
neurochemistry to the phenotypic expressions of schizophrenia. These 
neurobiological frameworks aim to accommodate structural and functional 
abnormalities and disconnectivity between brain regions. The dopamine 
hypothesis of schizophrenia still remains the most relevant theory linking the 
pathophysiology of positive symptoms to the mechanism of current antipsychotic 
medications. However, the development of the glutamatergic hypothesis 





of action and potential neurobiological target for treating core refractory 
symptoms. While these models are still in their infancy in explaining the aetiology 
of schizophrenia, their contribution to a neuropathophysiological framework of 
the brain usefully informs the manifestation and maintenance of core phenotypes. 
Further investigation and ongoing refinement of these models continues to 
advance the development of novel treatment interventions and their progression 
into clinical trials.  
 
1.3.1 Dopamine Hypothesis 
The initial hypothesis of excessive subcortical dopamine was derived from clinical 
benefits following administration of antipsychotics [37] and their potency for 
dopamine type-II (D2) receptors [38]. Neuroimaging studies provide evidence of 
D2 receptor hyperfunction in the mesolimbic pathway projecting from the ventral 
tegmental area to the nucleus accumbens [39] (Figure 1.1a). This increase in 
dopaminergic neurotransmission is associated with increased positive symptoms 
in schizophrenia and parallels fluctuations in psychotic episodes throughout the 
course of illness [40]. D2 receptors are highly concentrated in the striatum, with 
lower concentrations in the prefrontal cortex and medial temporal regions. 
Dopamine dysfunction in the striatum, which receives inputs from both the 
ventral tegmental area and nucleus accumbens (Figure 1.1b), has been proposed 
as a final common pathway and mechanism of positive psychotics symptoms [41]. 
Overactive D2 receptor expression in this region may also contribute to cortical-





Figure 1.1. Mesolimbic and mesocortical pathways related to the dopamine hypothesis of schizophrenia: a) over-active dopaminergic 
function in the mesolimbic pathway, projecting from the ventral tegmental area to the nucleus accumbens, contributes to the manifestation 
of positive symptoms; b) the striatum is highly dense in dopamine D2 receptors, receiving input from the ventral tegmental area and nucleus 
accumbens, and is the proposed final common pathway of positive symptoms in schizophrenia; c) under-active dopaminergic 
neurotransmission in the mesocortical pathway contributes to the manifestation of negative symptoms and cognitive deficits. DLPFC, 














Hypoactivation of dopamine in the mesocortical pathway (Figure 1.1c) may 
play an important role in the generation of negative symptoms and cognitive 
impairment [43-46]. Activation of dopamine type-I (D1) receptors located on 
glutamatergic neurons decreases presynaptic glutamate release, while those 
located on GABA interneurons promote inhibition of pyramidal neurons [47, 48]. 
Reduced D1 receptor binding in the prefrontal cortex has been observed in drug-
naïve schizophrenia patients and has shown to be associated with increased 
severity of negative symptoms and impaired cognitive performance [49]. Despite 
these associations, the dopamine hypothesis is limited to defining a 
pathophysiological understanding of psychosis. This neurobiological model is less 
able to define the aetiology of other neurotransmitter system dysfunction, such 
as glutamate, adenosine and serotonin, which accommodate broader phenotypic 
profiles in schizophrenia [50]. 
 
1.3.2 Glutamate Hypothesis  
Decreased NMDAr function is thought to underlie neuronal atrophy and reduced 
excitatory networks in schizophrenia [51, 52]. The glutamatergic hypothesis 
proposes a preliminary dysregulation in prefrontal NMDAr function, which alters 
downstream dopaminergic neurotransmission [53, 54]. Hypofunctional NMDArs 
in the prefrontal cortex result in a weak GABA tone, attenuating the inhibition of 
secondary glutamate release (Figure 1.2). Increased secondary glutamate leads to 
excessive release of dopamine in the mesolimbic pathway (for further review, see 






the dopamine hypothesis, as well as providing a neurobiological model inclusive 
of negative symptoms, cognitive deficits and additional structural and functional 
alterations reported in schizophrenia.   
Support for glutamate dysfunction comes from acute models of 
dissociative anaesthetics that block NMDArs and decrease glutamate availability 
in the prefrontal cortex. NMDAr antagonists such as Phencyclidine (PCP) and 
Ketamine have been shown to give rise to schizophrenia-like symptoms in 
individuals without psychiatric history [51, 56] and worsen symptoms in 
schizophrenia patients [57, 58]. These acute pharmacological models induce 
positive and negative symptoms in a dose-response manner [59] and model 
cognitive impairments [53, 60], thought disorder [61] and eye tracking 
abnormalities [62, 63] that are reminiscent of schizophrenia. NMDAr co-agonists, 
such as glycine, have shown to inhibit PCP-induced hyperactivity [64], providing 
further evidence of altered NMDAr function underlying core schizophrenia 
phenotypes.  
Patient studies report decreased glutamate levels in cerebrospinal fluid 
and increased NMDArs post-mortem [65]. This increase in NMDArs is likely a 
neuronal compensatory mechanism to manage the pervasive state of decreased 
glutamatergic function, which is evident throughout the chronicity of the disorder 
[66]. Individuals with complete dopamine D2 receptor blockade persist with 
positive symptoms [67], suggesting that psychosis is mediated by additional 
neurotransmitter networks beyond hyperactive dopaminergic function in the 









Figure 1.2. Schematic illustration of the glutamatergic hypothesis of 
schizophrenia.  N-methyl-D-aspartate receptor-mediated positive symptoms, 
negative symptoms and cognitive deficits in the glutamatergic model of 






























resonance spectroscopy techniques have failed to identify a consistent 
relationship between regional glutamate and glutamine levels across different 
stages of the disorder (for further review, see [68]). In order to inform the 
aetiology and maintenance of core refractory symptoms, there is need to clarify 
their relationship with the pathophysiology of altered NMDAr function in cortical 
and subcortical networks within the brain. 
 
1.3.2.1 Glutamatergic Neurotransmitters 
At resting potential, NMDArs are ligand-gated ion channels blocked by a 
magnesium (Mg2+) gate. This block is relieved when the membrane potential is 
depolarised, allowing an influx of calcium (Ca2+) to enter the neuron. For NMDArs 
to be activated, they require glycine (an NMDAr co-agonist) to bind to the NR1 
subunit and glutamate to bind to the NR2 subunit of the receptor. When this 
occurs, Ca2+ activates a second messenger system that alters pre- and post-
synaptic connections via long-term potentiation and long-term depression (for 
further review, see [69]). It is through this change in synaptic connection strength 
by which the brain learns and encodes new information. High levels of 
extracellular sodium (Na+) and high intracellular potassium (k+) concentrations 
allow Na+ pumps to reabsorb glutamate and amino acids back into the cell. 
Glutamate is either reabsorbed via this process or it is converted into glutamine 
by glial cells and transported to other neurons [70], before being converted back 
into glutamate. When high levels of glutamate accumulate outside of the cell and 





to enter the cell. This increased concentration of intracellular Ca2+ may lead to 
neuronal cell death or excitotoxicity and is likely a contributing factor of neuronal 
atrophy observed in schizophrenia [71].  
 
1.3.2.2 GABAergic Neurotransmitters 
Attention to GABAergic function in schizophrenia was rejuvenated following 
developments in dopaminergic and glutamatergic hypotheses. GABAergic neurons 
contribute to a holistic framework of both deficits [72] and potential therapeutic 
interventions [73] in schizophrenia. This is particularly relevant to understanding 
alterations in neuronal plasticity within the disorder, as both glutamate and GABA 
play an important role in filtering information transmitted to cortical pyramidal 
neurons. When information is transferred down the neuronal dendritic spine, 
GABAergic synapses moderate neuronal plasticity by filtering glutamatergic 
signals, before they propagate to the cell soma to generate an action potential (for 
further review, see [74]; Figure 1.3). Glutamatergic neurons provide the excitatory 
drive for GABAergic interneurons, whereby reduced glutamatergic function leads 
to a loss of inhibitory filtering and subsequent hyper-activation of pyramidal 
neurons (Figure 1.2). Therefore, reduced cortical function of glutamate may 
initiate GABA-mediated cognitive deficits in schizophrenia. 
 
 Neurobiological Alterations 
A structural model of schizophrenia is supported by findings of smaller whole brain 
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Figure 1.3. Gamma-aminobutyric acid filtering of pyramidal neurons. Gamma-
Aminobutyric Acid (GABA) interneurons filter (green vertical bar) excitatory inputs 
on the dendritic spines of cortical pyramidal neurons, before reaching the cell 
soma. When glutamatergic regulation of GABA interneurons is decreased, the 
GABA-mediated inhibitory filtering is reduced, resulting in hyper-activation of 








[75, 78, 79], enlarged ventricles [80], focal alterations of white matter tracts and 
brain atrophy in regions such as the prefrontal cortex [16]. Alterations in structural 
and functional connectivity appear evident across different stages of the disorder 
[81, 82] , while structural alterations in family members provide support for a 
genetic contribution (for further review, see [83]). Findings of neurobiological 
alterations in schizophrenia has facilitated the characterisation of different stages 
of the disorder, including the development of premorbid risk factors (for further 
review, see [84]). Individuals at high risk for developing psychosis are reported to 
have pronounced grey matter deficits [85], reduced whole brain volume, and left 
and right prefrontal and temporal lobe volume [76]. Diffusion tensor imaging 
techniques report that abnormal white matter development in temporal regions 
in schizophrenia predicts functional outcomes in later stages of illness [86].  
Neuroscience has directed much attention to understanding phenotypes 
arising from aberrant neuronal networks and integration between brain regions, 
suggesting that many phenotypes can only be explained by considering the 
relationship between a range of cognitive processes. Instead of attributing 
structural plasticity, symptoms are postulated to result from synaptic plasticity - 
the activity dependent modelling of the pattern and strength of synaptic 
connections (for further review, see [87]). A series of post-mortem studies report 
reduced excitatory feed-forward circuits extending from the auditory cortex (AC) 
in chronic patients [88, 89], which may result in poor adaptation to perceptual 
changes in the environment. A disconnectivity framework of schizophrenia 






but that these abnormalities are secondary to the more pervasive problem of 
deficient integration and communication of information [87].   
 
 Antipsychotic Treatments 
In the acute psychotic state, schizophrenia patients exhibit an increase in 
dopamine synthesis and synaptic dopamine concentration [90], providing a clear 
and logical link to first-generation antipsychotics (FGAs) targeting dopamine D2 
receptor function [91]. A limitation of FGAs, which includes agents such as 
haloperidol and chlorpromazine, is the manifestation of extrapyramidal side 
effects following acute and chronic D2 receptor blockade (Figure 1.4). Following 
administration of haloperidol, dopamine D2 receptor occupancy rates above 65% 
have demonstrated therapeutic efficacy, while occupancy rates above 78% 
elicited extrapyramidal side-effects and no further symptom improvement [91]. 
High doses of FGAs can also block activation in the mesocortical pathway, 
contributing to secondary negative symptoms and cognitive deficits [92]. 
The profound side effects of FGAs led to the development of second-
generation antipsychotics (SGAs). An advantage of SGAs is reduced specificity for 
dopaminergic receptors and indirect modulation of dopamine via other 
neurotransmitter systems. For example, risperidone and ziprasidone have a high 
affinity ratio for 5HT2A-to-D2 receptors, where 5HT2A has an additional regulatory 
effect on dopaminergic function (for example, see [93, 94]). These properties 
allow the drugs to maintain their therapeutic benefit while lowering the risk of 





benefits of SGAs, these drugs also incur increased cardio and metabolic side-
effects, such as weight gain and glucose dysregulation (for further review, see 
[95]). Overall, these treatments have not met expectations with regards to 
reduced side-effect profiles or increased tolerability when directly compared to 
FGAs (for further review, see [96]).  
Clozapine is almost considered a third class of antipsychotic, due to its 
ability to treat up to 50-60% of treatment-refractory patients (i.e. patients who 
have not previously responded to antipsychotic medication) [94, 97]. However, 
this drug demonstrates limited efficacy when administered to treat first episode 
psychosis [98]. Clozapine has lower-affinity and short-term high occupancy at D2 
receptors, which is sufficient to maintain antipsychotic properties without over-
occupying the receptor [99, 100]. In addition, clozapine has high affinity for 5HT2A, 
Muscarinic M1 and α2-adrenoceptors (for further review, see [101]), supporting 
significant involvement of neurotransmitter systems beyond direct dopamine 
activation that contribute to its effectiveness. There are additional adverse side 
effects involved in treatment with clozapine, most notably, haematological 
reactions, dose-related reduction in seizure threshold, myocarditis and cardio-
myopathy [102]. These risk factors require close monitoring, limiting the practical 
utility of administering clozapine in treatment-resistant or chronically ill patients.  
While antipsychotics show some efficacy in reducing psychotic symptoms 
and preventing relapse in schizophrenia [91, 103], they have modest effects in 
treating negative symptoms and cognitive deficits [104]. Recent large-scale clinical 











Figure 1.4. Antipsychotic blockade of dopamine D2 receptors. First generation 
antipsychotics have high affinity for dopamine D2 receptors, while second 
generation antipsychotics have high potency but reduced specificity for 
dopamine. Both acute and chronic blockade of D2 receptors contribute to the 







when assessing real world outcomes. The Clinical Antipsychotic Trial of                            
Intervention Effectiveness (CATIE) [105] and the Cost Utility of the Latest  
Antipsychotic Drugs in Schizophrenia Study (CUtLASS) [106] both failed to 
demonstrate superior efficacy for either FGAs or SGAs on measures of treatment 
discontinuation, improved psychotic symptoms, or increased quality of life. In a 
meta-analysis examining the efficacy of fifteen different antipsychotics, only small 
effects sizes were observed for amisulpride, olanzapine, and risperidone, all of 
which were developed in the first series of SGAs [107].      
 
 Glutamatergic Treatments 
The challenge for current pharmacological research is to address the under-
recognised and treatment refractoriness of core negative symptoms and cognitive 
deficits, and to optimise conditions for pharmaceutical benefit. A glutamatergic 
model postulates hypofunction of prefrontal NMDArs that lead to reduced 
excitatory networks and alterations in brain structure, function and downstream 
neurotransmitter pathways [55, 108-110]. Direct activation of glutamatergic 
receptors leads to neuronal cell death and is not a feasible option to manage the 
hypofunctional NMDAr state of schizophrenia. Alternatively, activation of the 
glycine modulatory site is one proposed mechanism of increasing glutamatergic 
neurotransmission (Figure 1.5). In animal models of schizophrenia, glycine 
reduced PCP-mediated psychotic symptoms [111, 112]. The same authors report 
glycine increased NMDAr-mediated inhibition of dopamine  release in the striatum 





Figure 1.5. Glycine binding on N-methyl-D-aspartate receptors. Directly activating the glutamate binding site on N-methyl-D-aspartate 
receptors (NMDArs) may lead to neuronal cell death or excitotoxicity. One alternative way to increase NMDAr function in schizophrenia is to 
activate the glycine modulatory site. Novel therapeutic targets aim to increase synaptic glycine concentrations to rectify the hypofunctional 




















(GT1-RI) stimulated NMDAr-mediated GABA release in the same region [114]. 
NMDAr agonists such as glycine [115-117] and D-serine [118, 119], as well 
as the glutathione precursor N-acetyl-cysteine (NAC) [120], have demonstrated 
improved clinical symptoms in patients on stable antipsychotic medication, 
although some studies have failed to replicate these findings (for further review, 
see [121]). While high-dose glycine has shown to improve negative symptoms 
[117, 122, 123] and cognitive deficits [124] in treatment-resistant patients, 
increasing synaptic glycine concentration under clozapine may saturate the 
glycine modulatory site and initiate increased negative symptoms; glycine may 
downregulate NMDAr activity [125] and D-cycloserine may displace fully occupied 
sites [126].  
Proof of concept studies administering GT1-RIs have shown promising 
results for improving positive and negative symptoms [127]. However, a recent 
phase-III clinical trial failed to support any benefit of the GT1-RI bitopertin when 
compared to placebo [128], raising doubts as to the benefit of increasing synaptic 
glycine concentration in schizophrenia. An editorial by Beck and colleagues [2] 
raises concern of secondary negative symptoms inflating a placebo effect, 
particularly in chronic patients. The authors further suggest the need for 
stratifying biological dysfunction in clinical trials and the need for biological 
markers to further inform mechanisms of treatment efficacy. Such markers may 
help clarify inconsistent reports on therapeutic outcomes following increased 







 Cannabis Use in Schizophrenia 
Substance use disorder is highly prevalent in schizophrenia, with approximately 
50% of substance use in patients compared to 16% in the general population [129]. 
Notably, cannabis use is significantly higher in schizophrenia [130, 131] and in 
individuals with a psychotic illness more generally [132]. A meta-analysis 
estimated the prevalence of a cannabis use disorder in schizophrenia, indicating 
clinically significant distress or impairment [11], for current use at 16% and 
lifetime use at 27.1% [133]. In the Australian and New Zealand Clinical Practice 
Guidelines cannabis is identified as the most serious comorbidity in schizophrenia 
due to its widespread use [134]. Cannabis has been reported to worsen outcomes 
in schizophrenia patients by enhancing cognitive deficits and psychotic symptoms 
and increases the risk of relapse [135-137]. Chronic cannabis users, without 
psychiatric history, also exhibit many cognitive phenotypes that are proposed 
vulnerability markers of schizophrenia [138]. 
 
1.7.1 Structural and Functional Alterations  
Disruption of normal endocannabinoid functioning may lead to alterations in brain 
networks important for neuronal and cognitive development [139]. Cognitive 
deficits in heavy and long-term cannabis users are thought to be mediated by 
alterations in the hippocampus, prefrontal cortex and cerebellum [140]. These 
regions are critically involved in memory and higher order cognitive processing 
and are dense with cannabinoid receptors [141, 142]. The most commonly 






and verbal learning and memory, with some evidence of ongoing impairment after 
prolonged cessation of use (for further review, see [143]). These findings are 
supported by animal models reporting learning and memory impairment after 
acute and chronic cannabinoid administration [144, 145]. 
Similarities in structural and functional deficits between cannabis users 
and schizophrenia patients suggest a common underlying pathology [138]. 
Reduced hippocampal volume in cannabis users has been associated with 
cumulative exposure to cannabis and increased development of subclinical 
psychotic symptoms, where hippocampal reductions were of similar magnitude to 
that observed in schizophrenia [146]. Molecular and electrophysiological 
techniques have been used to demonstrate cannabinoid type-I (CB1) receptor 
mediation of Δ9-Tetrahydrocannabinol (Δ9THC) induced reductions in long-term 
potentiation [147]. In this study, Δ9THC was shown to down-regulate 
glutamatergic receptor subunits in mice and induce their endocytosis via CB1 
receptors. Repeated exposure to cannabis has also been shown to suppress long-
term potentiation in the CA1 region of the hippocampus [148, 149]. These findings 
suggest a complex interaction between endocannabinoid and glutamatergic 
neurotransmitter function that is adversely affected by repeated Δ9THC exposure.  
 
1.7.2 Endogenous Cannabinoids 
Endocannabinoids and their receptors modulate physiological functioning in a 
range of neuronal networking systems within the brain [150] and play an 






memory [151]. The two main cannabinoid receptors, CB1 and cannabinoid type-II 
(CB2), belong to the family of G-protein coupled receptors. CB1 receptors are 
expressed in the central nervous system (CNS), with highest concentrations in the 
basal ganglia, hippocampus, and prefrontal and anterior cingulate cortex, while 
CB2 receptors are mainly found in the immune cells and peripheral tissues [152]. 
Endocannabinoids are lipid transmitters that serve as natural ligands for 
cannabinoid receptors, with the main endocannabinoids being 
arachidonoylethanolamide (anandamide or AEA) and 2-arachidonoylglycerol (2-
AG). Endocannabinoid synthesis is located on membrane phospholipids in 
response to postsynaptic intracellular CA2+, a process that may be aided by post-
synaptic G-protein couple receptor activation.  
Cannabinoid receptors mediate the inhibition of neurotransmitter release 
throughout the central nervous system, including glutamate, dopamine and GABA 
[153-155]. Depolarised induced suppression of excitation (DSE), the process of 
inhibiting neurotransmitter release from glutamatergic neurons, occurs when CB1 
receptors inhibit voltage-gated Ca2+ channels and K+ conductance [156]. DSE 
occurs when 2-AG is released from CA1 pyramidal neurons during depolarisation 
and act in a retrograde manner to activate CB1 receptors on Schaffer collateral 
axon terminals [156]. CB1 receptors regulate activation of NMDArs, via coupling of 
histidine triadnucleotide-binding protein 1 (HINT-1) [157], to prevent further CA2+ 
influx and therefore protect against neuronal excitotoxicity. As NMDArs become 
highly activated, cannabinoids are recruited on demand to co-internalise the NR1 






synaptic messaging [158].  
 
1.7.3 Exogenous Cannabinoids 
The endocannabinoid system is the binding site of exogenous cannabinoids, such 
as Δ9-THC, which disrupt normal endocannabinoid regulation of neuronal 
excitability within the brain [159]. Δ9THC is the main psychotropic constituent in 
cannabis [160] and is a partial agonist at CB1 and CB2 receptors. CB1 receptors 
located on glutamatergic neurons appear to be activated at lower concentrations 
of Δ9THC compared to those on GABAergic neurons, suggesting a bell-shaped 
dose-response excitatory curve [161]. Cannabidiol (CBD), also an exogenous 
cannabinoid found in cannabis plant matter and partial agonist at CB1 and CB2 
receptors, has purported anxiolytic and antipsychotic properties (for further 
review, see [162]). Although CBD has low affinity at CB1 receptors, it has negative 
allosteric modulator properties [163, 164] that reduce the ability of CB1 agonists, 
such as Δ9THC, to bind to the receptor.  
Increased activation of CB1 receptors has been shown to induce psychotic 
states in vulnerable individuals [165, 166] and worsen symptoms in schizophrenia 
patients [135]. Alterations in endocannabinoid regulation of glutamatergic 
function, whereby CB1 receptors restrict NMDAr activation, may lead to prolonged 
states of NMDAr hypofunction or downregulation of NMDArs, conditions that are 
synonymous with the pathophysiology of schizophrenia (see section 1.3). Over-
activation of pre-synaptic CB1 receptors may inhibit glutamate release in the 






pathways. Prolonged states of reduced NMDAr signalling may lead to alterations 
in downstream neurotransmitter functioning, such as dopamine [167], providing 
a mechanism for which repeated exposure to Δ9THC may precipitate psychotic 
symptoms in vulnerable individuals.   
It is unclear whether smoked cannabis alters CB1-NMDAr associations to 
differentially affect the neuronal response to NMDAr-mediated treatments in 
schizophrenia. The efficacy of increasing synaptic glycine concentration may be 
reduced under conditions of elevated CB1-mediated inhibition of NMDAr 
activation. While most of the pharmacological action of exogenous cannabinoids 
is reported for CB1 receptors, Δ9THC and CBD may also alter glutamatergic and 
GABAergic function via CB1-independent mechanisms (for review of additional 
molecular targets not discussed here, see [168]). In neurons located in the ventral 
tegmental area in mice, Δ9THC potentiates glycine receptor-mediated currents via 
allosteric mechanisms in a dose-response manner [161]. These findings suggest 
exogenous cannabinoids alter neural activation and downstream 
neurotransmitter release in brain networks implicated in the pathophysiology of 
core schizophrenia phenotypes (see section 1.3.1). Of particular relevance to the 
current thesis is that different combinations of Δ9THC and CBD potency found in 
cannabis plant matter [169], as well as evidence for their dose-dependent 
outcomes (for further review, see [170]), may lead to differential effects of 
cannabis on NMDArs and associated signalling pathways.  There is need to further 
clarify the effects of repeated cannabis use on vulnerability markers indexing 






 Chapter Summary 
While neuroscience has advanced our understanding of the biological 
underpinnings of schizophrenia, there remains vast heterogeneity in response to 
pharmacological treatments. A dopaminergic hypothesis provides a clear link to 
antipsychotics targeting dopamine D2 receptor function. However, a 
glutamatergic hypothesis proposes preliminary dysregulation that accommodates 
core refractory symptoms and cognitive deficits, specifying NMDArs as a logical 
neuronal target for pharmacological intervention. The shift from a narrowly 
defined dopamine hypothesis, to the refinement of broader neurobiological 
models such as glutamate, has guided the development of alternative treatments 
which are progressing through preclinical and clinical phases of testing. A 
challenge for current neuropsychopharmacological research is to clarify 
mechanisms of improved clinical outcomes and to increase the specificity and 
sensitivity of diagnostic and treatment tools [171].  
Increasing synaptic glycine concentration is one potential method to 
rectify the hypofunctional NMDAr state in schizophrenia. Phase-II clinical trials 
have found some evidence that this method improves positive and negative 
symptoms [119, 127, 172, 173], while other studies have failed to replicate these 
findings [128]; this raises some doubt as to the benefit of increasing post-synaptic 
glycine concentrations in schizophrenia. The endocannabinoid system plays a key 
role in regulating NMDAr activation and disruption of this regulatory mechanism, 
such as that following regular cannabis use, may alter neurotransmitter 






of the endocannabinoid system (both related and unrelated to regular cannabis 
use) on cortical and subcortical networks deficient in schizophrenia, may help to 
inform mechanisms of core refractory phenotypes. The application of biomarkers 
in glutamatergic-mediated pharmacotherapy trials may be a useful means of 
informing the relationship between functional target engagement and improved 
clinical outcomes. Further, they may help clarify inconsistent reports on the 
benefits of increasing synaptic glycine concentration to improve clinical symptoms 





















2.1 Chapter Introduction 
In pharmacotherapy trials, biomarkers aim to clarify the relationship between 
neuronal occupancy and expected therapeutic benefits. Absence of such 
measures in preclinical trials can make it difficult to interpret inconsistent reports 
on clinical outcomes, as is the case for treatments that aim to increase synaptic 
glycine concentration in schizophrenia. The primary auditory pathway is one 
neurobiological system that allows unique insight into the integrity of excitatory 
neurotransmitter functioning within the brain. Mismatch Negativity (MMN) is a 
measure of auditory change detection and is a potential biomarker to index N-
methyl-D-aspartate receptor (NMDAr) hypofunction in schizophrenia. There is 
need to determine the nature of the relationship between MMN and NMDAr 
function, in order to inform the utility of MMN to index neuronal integrity in brain 
regions and pathways underlying core refractory symptoms. 
 The following chapter defines MMN as an event-related potential indexing 
deviance detection and discusses the pharmacology of its generation, with 
particular focus on neuronal networks and brain regions relevant to the 
pathophysiology of schizophrenia. Discussions on the hierarchical structure of the 
primary auditory pathway and networks involved in processing frequency and 
duration sound features, provide a framework to discuss the contribution of 
excitatory and inhibitory networks involved in MMN generation. This chapter 
reviews MMN findings within schizophrenia and proposes MMN as a potential 
biomarker to stratify NMDAr dysfunction within the disorder. Further, this chapter 





function following neuronal target engagement of pharmacological treatments. 
 
2.2 Mismatch Negativity Defined 
MMN indexes the brain’s pre-attentive ability to detect stimulus change in sensory 
memory. Auditory MMN is a negative deflection of the event-related potential 
(ERP), elicited above the threshold of discrimination between a deviant stimulus 
and a pattern of sounds forming a sensory memory trace [174, 175]. Deviant 
stimuli may vary from the memory trace, also referred to as standards, in differing 
complexity, such as change in spectral, temporal, or higher order features [176, 
177] (higher order constructs such as phonetic structure, sequence pattern and 
stimulus omission are not discussed here). Typically, MMN is calculated by 
subtracting the ERP to standards from the ERP to deviants, creating a difference 
waveform (see section 2.2.1). The negative potential observed in the difference 
waveform is thought to index additional excitatory processing required for 
deviance detection. As MMN is a pre-attentive measure of attention and is 
responsive to neurobiological change, it is a candidate biomarker for translational 
clinical research.  
 
 Electroencephalographic Measurement 
MMN is elicited approximately 100-200ms after the onset of a deviant stimulus 
[178]. It is typically measured by recording ongoing spontaneous neuronal activity 
via electroencephalograph (EEG) at frontal electrode sites, compared to a 






The EEG recording at each electrode indexes the voltage signal of many neurons 
working together across time-varying domains. The latency of the ERP indexes 
both the degree of neural activity required to process the stimulus and ongoing 
neural activity that is non-specific to the stimulus.  In order to remove the non-
specific or irrelevant neural activity, multiple ERP trials to the same stimulus 
presentation are averaged together. This method assumes that neural activity 
generated in response to the stimulus will be most prominent in the averaged 
waveform due to its consistent temporal presentation across trials, while the non-
specific activity is ‘averaged out’ along the temporal domain of the ERP recording.  
 
 Oddball Paradigm 
Typically, much research has utilised an auditory oddball paradigm to measure 
MMN, whereby deviant tones are presented intermittently within a background 
of identical standard tones (Figure 2.1). The number of standard tones is 
presented at differing train lengths to allow the deviant stimulus to be presented 
at unexpected time intervals and of an unknown probability. The deviant tone may 
be characterised by, but not limited to, changes in duration, frequency, intensity, 
or spatial location of a sound. The average response to all standard tones is 
subtracted (separately) from the averaged response to each type of deviant tone, 
creating a difference MMN waveform for each deviant type.  
 
 Roving Paradigm 





deviant throughout the MMN sequence and is randomly repeated in blocks of 
differing train lengths. The first stimulus in each block functions as a deviant 
stimulus, due to the relative change in sound properties from the preceding block 
(Figure 2.2a). Rather than reverting back to the same standard stimulus, as is 
typical in an oddball paradigm, the roving design continues to repeat the ‘deviant’. 
After two-to-three presentations, the deviant stimulus is processed as a new 
series of standards (Figure 2.2b). Therefore, the relative presentation order of a 
stimulus defines it as a deviant or standard (Figure 2.2c). MMN waveforms are 
calculated for each stimulus type separately, in order to control for sound 
properties. This is achieved by subtracting the averaged standard ERP from the 
averaged deviant ERP across stimuli with identical sound features (Figure 2.2c).  
 
2.3 Mismatch Negativity Generators 
MMN has traditionally been defined as an index of functioning in auditory cortical 
networks required for deviance detection. The most consistently reported 
generators of MMN include the temporal and frontal cortices [176, 180, 181]. 
Functional magnetic resonance imaging (fMRI) has shown increased activation in 
the superior temporal gyrus of the auditory cortex (AC) in response to deviant 
tones [182]. The AC is proposed to detect sound features and establish a memory 
trace to which incoming stimuli are compared [174]. Cerebral blood flow, EEG and 
scalp current density analyses have provided evidence for an additional frontal  
generator in the inferior frontal gyrus (for further review, see [183]), with evidence 









Figure 2.1. Mismatch negativity oddball paradigm. In an oddball mismatch negativity paradigm, a series of standard stimuli [blue] are 
presented at differing train lengths to establish a memory trace in auditory sensory memory. Deviant stimuli [red] (i.e. deviating from the 








Figure 2.2. Mismatch negativity roving paradigm. In a roving mismatch negativity (MMN) paradigm, different stimuli are presented in 
blocks of varying train length: a) The first tone in the new block functions as a deviant (red deviant), due to the change in sound properties 
relative to the preceding memory trace (blue memory trace); b) The deviant tone is repeated in order to establish a new memory trace of 
identical sound features (red memory trace); c) The MMN difference waveform is calculated for each stimulus type separately, whereby the 
event-related potential (ERP) of the standards (for example, the average of all  green memory traces) is subtracted from the ERP of 
corresponding deviant stimuli (for example, the average of all green deviants). 







gyrus [184], while frequency deviants activate the right inferior frontal gyrus [182, 
184]. Frontal activation is related to an involuntary switch in attention that is 
required for higher-level deviance detection when comparing a stimulus to an 
established memory trace [184-186].  
 
2.4 Stimulus-Specific Adaptation  
The generation of MMN is thought to result from a series of deviance detection 
processes occurring in both subcortical and cortical structures of the auditory 
pathway. Stimulus-specific adaptation (SSA) is a form of short-term plasticity in 
response to a repeated stimulus. When the same stimulus is repeated, such as 
standard tones in an oddball paradigm (see section 2.3.1), the neuronal activation 
in response to the stimulus is reduced. Following the presentation of a deviant 
stimulus, the firing rate of the same neurons are significantly increased, releasing 
the suppression of neuronal firing imposed on the repeated stimulus [187]. This 
finding supports the separation of the SSA response from an independent model 
of neuronal fatigue. SSA in response to deviant stimuli are well developed in 
regions of the midbrain [188], suggesting that SSA contributes proportionally to 
deviance detection processes generated higher in the auditory pathway, including 
MMN. While SSA contributes to deviance detection via bottom-up processing of 
sound features, corticofugal projections from the AC help to modulate the firing 
rate of neurons in midbrain structures [189] (corticofugal projections supporting 






2.5 Prediction Error Encoding  
The magnitude of the MMN is dependent on the strength of the standard pattern 
in echoic memory, implicating an important role of synaptic plasticity in MMN 
generation. The detection of a deviant stimulus requires on-line modification of 
the established memory trace [190], such that the brain receives bottom–up 
thalamic inputs which inform current stimulus properties and allow the brain to 
adjust top–down predictions [191, 192]. A model of prediction error defines MMN 
as the difference between these thalamic inputs and NMDAr spike timing of a 
dependent synaptic plasticity discharge, which occurs when information is fed-
back to predictive neurons. This model suggests reduced efficiency in having learnt 
the regularity of the predictive rule (the standard memory trace), or impairment 
in detecting or communicating the response to an unexpected deviant stimulus. 
In the latter case, MMN is considered a prediction error signal of the acoustic 
environment [193, 194].  
 
2.6 Auditory Processing Hierarchy  
Processing of auditory sound features begins in the cochlear nucleus. Neuronal 
signals ascend through the inferior colliculus (IC) to the medial geniculate body 
(MGB; part of the auditory thalamus). The cytoarchitecture of the MGB suggests 
that spectral and temporal properties are deconstructed, prior to being processed 
in core areas of the primary (AI) and secondary (AII) AC [195]. The frontal cortex 
tracks the violation of expected sounds by comparing change in stimulus features, 






 The descending cortico-thalamic and cortico-collicular pathways assist in 
neuronal adaptation and deviance detection at the level of subcortical structures 
[189]. Descending projections to the MGB and IC primarily extend from layer V 
and VI of the AI [197-199]. The MGB has a high ratio (10:1) of corticofugal 
projections compared to the corresponding ascending pathways [200, 201]. These 
projections demonstrate strong stimulus-specific adaptation, indexing a gain 
control mechanism of the AC to MGB neurons. Corticofugal projections update 
sensory representation of sounds, via synaptic depression, which is then projected 
back to higher order cortical areas [202, 203]. Sounds features are then integrated 
in the belt and parabelt areas surrounding the AI and AII, before projecting to the 
frontal and parietal cortices for higher order processing required for deviance 
detection [195].  
 
2.6.1 Frequency Sound Processing 
Tonotopic maps are the spatial arrangement of different laminae or bands 
sensitive to differing sound frequencies. These maps ascend through the auditory 
pathway in a bottom-up fashion, allowing the processing of sound frequency to 
be communicated directly to corresponding bands in the next level of the 
ascending auditory pathway [204]. Projections extending from the central nucleus 
of the IC, to the ventral division of the medial geniculate body (MGBv) and AI, form 
the leminiscal pathway of the auditory system. Neurons in the leminiscal pathway 
are of short latency, sharp tuning curve, and have a consistent neuronal response 





organisation in the leminiscal pathway also extends to belt areas of the AC [206-
208].  
 
2.6.2 Duration Sound Processing 
Within the brainstem, neurons are non-selective to the duration of a sound, 
having a sustained response to the duration of all auditory stimuli. Within the IC, 
further along the ascending auditory pathway, duration-tuned neurons have a 
neurophysiological response characterised by specific stimulus durations. These 
duration-tuned neurons have also been reported in areas of the auditory thalamus 
and AC in mammals [195, 209]. The selective activation of duration-tuned neurons 
occurs via excitatory inputs corresponding to the onset and offset of a stimulus, 
while temporally offset inhibitory inputs supress the excitatory response occurring 
at neurons of non-corresponding durations [195, 210]. Projections from the IC to 
the medial (MGBm) and dorsal (MGBd) divisions of the MGB and belt areas of the 
AC are less tonotopically organised, forming the non-leminiscal pathway of the 
auditory system. In the MGBd, neurons are typically of broad tuning curve, while 
the MGBm appears to have both broad and narrow-tuned neurons to allow more 
accurate discrimination between different sound durations [205]. The leminiscal 
and non-leminiscal pathways are not mutually exclusive, rather, temporal and 
spectral processing occurs parallel to allow complex integration of differing sound 
properties. Corticofugal projections from the AC descend primarily to the non-
leminiscal subcortical structures of the MGB and IC [211]. The processing of 






connectivity across a range of ascending and descending neuronal projections 
between subcortical and cortical regions.  
 
2.7 Pharmacology of Mismatch Negativity 
The pharmacological underpinnings of MMN have been investigated by 
modulating different neurotransmitter system functioning [212]. Auditory sensory 
memory, like other areas of working memory, involves a complex interaction of 
excitatory and inhibitory processes. The most robust and consistent 
pharmacological modulation of MMN has been demonstrated by altering NMDAr 
function (for further review, see [213, 214]). Minimal effects have been reported 
following modulation of dopaminergic [215], serotonergic [214, 216, 217] and 
gamma-aminobutyric acid (GABA) type A [218] receptor modulators. MMN 
appears heavily dependent on glutamatergic function, the main excitatory 
neurotransmitter system in the brain, and more specifically on excitatory 
pyramidal neurons [87].  
 
2.7.1 Glutamate 
Several studies have reported MMN reductions in humans following acute 
ketamine administration, an NMDAr antagonist, for both frequency and duration 
deviants [214, 219-222]. Two studies failed to replicate these findings: Oranje and 
colleagues [223] suggest that their negative findings may reflect low plasma level 
of ketamine at 158ng/ml, compared to 426ng/ml reported in an earlier positive 





and reported similar low plasma levels (133.8±58.2ng/ml) comparable to previous 
negative findings. Further support for a critical role of NMDAr function in 
generating MMN comes from administration of other NMDAr antagonists 
including Nitrous Oxide (N20) gas [199] and memantine [200]. At low doses, 
memantine increased MMN amplitude, potentially due to the ability of 
memantine to increase glycine affinity when administered at low doses [201].  
Contrary to expectations that glycine would increase MMN amplitude, high-
dose glycine reduced duration MMN amplitude in healthy controls [225]. In that 
study, participants were administered 0.8g/kg of glycine, the dose typically 
reported for clinical benefits in schizophrenia. The observed reduction in MMN 
amplitude may be indicative of a worsening in pre-attentive change detection in 
individuals with intact glutamatergic function prior to glycine administration. This 
interpretation is supported by animal models reporting cognitive impairment 
beyond optimal levels of synaptic glycine concentration [226]. These findings 
suggest a dose-dependent relationship between glycine and NMDAr function prior 
to glycine administration, whereby glycine may increase MMN amplitude in those 
with relatively low baseline NMDAr function, such as in schizophrenia, while 
reducing MMN amplitude in those with normal baseline functioning. However, the 
nature of this relationship has not been examined directly.  
 
2.7.2 Dopamine 
Modulating dopamine signalling has yielded a weak association with MMN 






dopamine type-II (D2) receptor agonists, or pergolide, a dopamine receptor type-I 
(D1) and D2 receptor agonist, on MMN amplitude [215, 227]. No changes in MMN 
were observed following growth hormone response to apomorphine (non-
selective dopamine agonist) or clonidine (an ą2 adrenergic agonist) [228], 
providing indirect evidence that MMN generation is not dependant of 
dopaminergic function. In addition, inhibiting the reuptake of dopamine and 
norepinephrine under methylphenidate did not affect MMN [229]. Of three 
studies that have investigated the effects of haloperidol, a dopamine D2 receptor 
antagonist and antipsychotic treatment for schizophrenia (see section 1.5), two 
studies reported no effects on MMN amplitude [230, 231]. Only one study 
reported that haloperidol reduced MMN amplitude in healthy controls, in addition 
to increasing other selective and non-selective components of the ERP [232].  
 
2.7.3 Cannabinoid 
Altered synaptic plasticity in regular cannabis users [148, 233] is thought to occur, 
in part, due to cannabinoid type-1 (CB1) receptor-mediated downregulation of 
NMDArs [147, 148]. An acute administration study of exogenous cannabinoids 
found Δ9-Tetrahydrocannabinol (Δ9-THC) did not affect MMN amplitude in healthy 
controls, while co-administration of Δ9-THC and cannabidiol (CBD) increased MMN 
amplitude [234]. These effects of Δ9-THC have shown to be mediated by the 
neuregulin 1 gene [235, 236], while in a separate study, the CB1 receptor agonist 
rimonabant reduced MMN amplitude [237]. Roser and colleagues [237] reported 





frequency MMN, but long-term and heavy cannabis users showed smaller 
frequency MMN amplitude at frontal sites when compared to shorter-term and 
lighter cannabis users. Rentzsch and colleagues [238] reported attenuated 
frequency MMN amplitude in abstinent users and while no differences were found 
in that study between chronic cannabis users with and without schizophrenia, 
both patient groups had smaller MMN amplitude compared to controls.  
Interestingly, group differences in each of these studies were primarily 
highlighted for the MMN component elicited by a frequency deviant; although 
both studies included a duration deviant condition, neither study reported any 
group differences for duration MMN. Pesa and colleagues [239] reported an 
altered pattern of duration MMN in first-episode psychosis patients who used 
cannabis, relative to patient nonusers. In that study, increased quantity and 
frequency of recent cannabis use was associated with smaller duration MMN 
amplitude. More recently (and since the publication of our findings in chapter 
four), Impey and colleagues [240] reported reduced duration MMN amplitude in 
nicotine naïve cannabis users. Together, these findings suggest that longer periods 
of heavy cannabis use may reduce MMN amplitude. Given the prevalence of 
cannabis use in patients within schizophrenia [133] and the effects of the 
endocannabinoid system in regulating NMDAr function [217], further clarification 
of the relationship between current regular cannabis use and MMN is required 








2.8 Mismatch Negativity in Schizophrenia 
Reduced MMN amplitude in schizophrenia is a robust phenotype, with a meta-
analysis of studies reporting a large mean effect size (Cohen’s d>1) [241].  An 
earlier meta-analysis separately reported a large effect size for duration MMN 
(d=1.01) and a medium effect size for frequency MMN (d=0.47) [242]. Smaller 
MMN amplitude has been associated with impaired daily functioning [243] and 
cognitive deficits [244]. Todd and colleagues [212] propose that MMN is more 
likely to index stable features of schizophrenia, however the relationship between 
MMN and discrete clinical symptoms or functional outcomes has not been 
consistently reported (for further review, see [89]). Clarifying the nature of the 
relationship between MMN, NMDAr function and discrete phenotypes in 
schizophrenia, may inform mechanisms of core clinical features and changes in 
neurobiological function underlying clinical treatment efficacy.  
As is the case in MMN more broadly, the degree of MMN generation in 
schizophrenia is influenced by stimulus features, such as the degree of perceptual 
discrimination between standards and deviants and the predictability of a deviant 
presented within a standard memory trace [245]. Greater differentiation between 
a deviant stimulus and the memory trace typically elicits a larger MMN response 
[174, 192]. What is thought to be deficient in schizophrenia is the ability to 
produce larger MMN amplitudes with increasing stimulus deviance, as the MMN 
amplitude appears to plateau earlier compared to controls along a continuum of 
increasing stimulus discrepancy [246]. Therefore, greater differences between 





stimulus features.  
Reduced MMN to duration deviants is a robust finding in patients with 
early onset schizophrenia and has been shown to be impaired in the prodromal 
phase of illness and those at risk of developing psychosis [247-249]. Longitudinal 
evidence provides further support for MMN as a translational biomarker, with 
smaller MMN amplitudes predicting conversion to schizophrenia [247, 248]. In 
contrast, attenuated frequency MMN amplitude has been associated primarily 
with chronic schizophrenia illness [250]. These findings of frequency MMN deficits 
are thought to relate to the tonotopic organisation of the AC and alterations in 
plasticity with disease progression [250-253]. Smaller MMN generation in 
schizophrenia is unlikely due solely to the generation of MMN in the frontal cortex, 
as MEG studies have also demonstrated deficient MMN generation in patients and 
this measure is insensitive to frontal cortical activation [254]. While differences for 
duration versus frequency MMN do not offer clear discrimination of 
neurotransmitter functioning involved in the stage or severity of illness [255], 
MMN overall appears sensitive to changes in NMDA neurotransmitter function 
throughout the disorder.   
 
2.8.1 Antipsychotic Medication 
The use of antipsychotic medications does not significantly impact MMN 
amplitude in schizophrenia patients. Both clozapine and haloperidol have thus far 
failed to consistently modulate MMN amplitude, while clozapine consistently 






they tend to persistent despite ongoing antipsychotic medication. This is contrary 
to the pattern of sensory gating deficits, which are more reliant on dopaminergic 
function and typically resolve following reduced psychotic symptoms treated with 
antipsychotics [259]. These findings indicate that MMN is related to 
neurochemical imbalances independent of dopaminergic functioning and may be 
a useful tool for examining pharmacological underpinnings of the disorder in 
relation to glutamatergic models [260].  
 
2.8.2 Glutamatergic Treatments 
A 60-day trial of N-acetyl-cysteine (NAC), a glutathione precursor, significantly 
increased MMN in schizophrenia, without affecting the P300 component. It is 
unclear in this study whether the effect of increased MMN amplitude is from 
cysteine properties enhancing NMDAr function, or other mechanisms such as 
redox-sensitive transcription factors (or both) [261]. Magnetic resonance 
spectroscopy findings have reported that smaller duration MMN amplitude is 
associated with reduced glutathione levels in the posterior medial prefrontal 
cortex and further associated with increased negative symptoms in schizophrenia 
[262]. Using structural equation modelling, MMN has also been reported as an 
intermediary biomarker between glutamate dysfunction and verbal learning 
memory deficits in patients [263]. This study found smaller duration MMN was 
associated with reduced glutamate, GABA and glutamate-to-glutamine ratios in 
the medial prefrontal and anterior cingulate regions in schizophrenia. Together, 





smaller MMN amplitudes in schizophrenia and support the utility of MMN as a 
biomarker to index change in NMDAr function following treatment administration. 
 
2.9 Chapter Summary 
MMN may be a useful biomarker of functional target engagement to help clarify 
the relationship between NMDAr-mediated treatments and therapeutic efficacy 
in schizophrenia. However, few studies have investigated the pharmacology of 
altered MMN in schizophrenia directly, particularly following administration of 
NMDAr-mediated treatments. Findings from Leung and colleagues [225] suggest 
that high-doses of glycine (0.8g/kg) may reduce (rather than increase) MMN in 
those with intact baseline NMDAr function, supporting the presence of an 
Inverted-U dose-response relationship between synaptic glycine concentration 
and cognitive performance in humans. Determining the nature of this relationship 
is particularly important due to the heterogeneity of NMDAr dysfunction within 
schizophrenia [53-55]. 
Given the regulatory mechanism of endocannabinoids on NMDAr 
activation via pre- and post-synaptic mechanisms (see section 1.7.2), it is 
reasonable to assume that cannabis exposure reduces MMN following regular use, 
and may prevent the efficacy of increased synaptic glycine concentration to 
improve NMDAr function. Early findings suggest that cannabis does not alter the 
observed MMN deficit in schizophrenia [238], while prolonged and heavier 
cannabis use in healthy controls [237], and more frequent and heavier use in first 






be that in healthy controls the effects of cannabis use are more pronounced, while 
a floor effect of reduced MMN in patients restricts observation of further 
impairment in MMN following exposure to cannabis. Such findings may confound 
the utility of MMN to index neurobiological function related to the 























3.1  Literature Summary 
Increasing synaptic glycine concentration may assist in treating core refractory 
symptoms in schizophrenia. However, inconsistent reports of therapeutic efficacy 
have raised doubt as to the benefit of such treatments. Endocannabinoid-
mediated alterations in NMDAr excitability may modulate neuronal functioning in 
target pathways of NMDAr-mediated treatments. Cannabinoid receptor type-I 
(CB1) agonism, following repeated cannabis use, may lead to increased inhibition 
of NMDArs and potentially reduce the clinical efficacy of increasing synaptic 
glycine concentration in schizophrenia. Peripheral markers, such as plasma glycine 
or Δ9-Tetrahydrocannabinol (Δ9-THC) concentrations, are limited in informing 
neuronal functioning within the brain. Utilising biomarkers that index 
neurotransmitter functioning in brain networks involved in the pathophysiology 
of schizophrenia may help clarify the neurobiological relationship between neural 
target engagement and therapeutic efficacy following pharmaceutical 
intervention.  
The primary auditory pathway is one neurobiological system which may 
inform changes in neuronal functioning following administration of NMDAr-
mediated treatments. Specifically, MMN may inform the neuronal integrity of 
NMDArs following increased synaptic glycine concentration in schizophrenia. Few 
studies have examined the direct pharmacological modulation of MMN using 
NMDAr agonists in patients, while early evidence suggests that the relationship 
between synaptic glycine concentration and NMDAr function is characterised by 





glycine-mediated treatments may depend on NMDAr function prior to treatment 
administration. MMN may be a useful biomarker to stratify neurobiological 
dysfunction of NMDArs in schizophrenia and index mechanisms of improved 
clinical symptoms following neuronal target engagement of NMDAr-mediated 
treatments.  
 
3.2 Thesis Aims  
The aim of the current thesis is to determine the nature of the relationship 
between MMN and NMDAr function, in order to inform the utility of MMN as a 
biomarker to stratify NMDAr dysfunction and index neuronal target engagement 
of NMDAr-mediated treatments in schizophrenia. To achieve this aim, we 
investigated the relationship between MMN and altered NMDAr function in three 
independent studies, following: prolonged periods of regular cannabis use in 
otherwise healthy individuals; acute and chronic administration of glycine in 
schizophrenia patients; and a glycine dose-dependence trial in healthy controls. 
There was no participant overlap between studies described in this thesis.  
 In chapter four we investigate the effects of regular cannabis use on MMN 
by comparing current regular cannabis users against a sample of healthy age- and 
gender-matched nonuser controls. Given the role of the endocannabinoid system 
in regulating NMDAr function and glutamate release within the brain, it is 
important to know whether regular cannabis use alters neuronal functioning in 
target pathways of novel NMDAr-mediated treatments. Based on models of 





exposure to exogenous cannabinoids, we hypothesise  that  individuals with  
prolonged and heavy cannabis use will have smaller MMN amplitudes compared 
to matched controls.  
In chapter five we investigate whether an acute dose and repeated 
administration of glycine increases MMN amplitude in schizophrenia patients. 
Further, we investigate whether baseline and changes (from baseline to post-
glycine) in MMN amplitude are associated with change in clinical symptoms 
following 6-weeks of adjunct glycine treatment. Given inconsistent reporting of 
therapeutic benefits following NMDAr-mediated treatments in schizophrenia, 
there is need to establish biomarkers, such as MMN, to index neuronal target 
engagement and further inform the mechanisms of therapeutic efficacy. We 
hypothesise that acute glycine (0.2g/kg) and adjunct glycine treatment 
(0.6g/kg/day; 6-weeks) will increase MMN amplitude in schizophrenia. We also 
hypothesise that smaller baseline MMN amplitude (indicating poorer NMDAr 
functioning) will be associated with greater improvements in clinical symptoms 
following adjunct glycine treatment.  
In chapter six we investigate the dose-response relationship between glycine 
and MMN in an independent sample of healthy controls. Following the outcomes 
of chapter five and further evidence suggesting glycine may only exert therapeutic 
benefits within an optimal range of synaptic glycine concentration, we compare 
the effects of placebo and three different glycine doses (0.2g/kg; 0.4g/kg; 0.8g/kg) 
on MMN generation. We hypothesise an Inverted-U dose-response relationship 





findings of previous chapters are summarised and discussed, as well as their 
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7.1 Scope of the Thesis 
The aim of the current thesis was to determine the nature of the relationship 
between mismatch negativity (MMN) and alterations in N-methyl-D-aspartate 
receptor (NMDAr) function. Understanding this relationship is important as it 
informs the utility of MMN to stratify NMDAr dysfunction in schizophrenia and to 
index functional target engagement following NMDAr-mediated treatments. In 
order to achieve this overarching aim of the thesis, three independent empirical 
studies were performed: The first study (chapter four) aimed to determine 
whether MMN is smaller in regular cannabis users compared to controls; the 
second study (chapter five) aimed to determine the effects of acute and repeated 
glycine administration on MMN in chronic schizophrenia patients and its relation 
to treatment outcomes; the third study (chapter six) aimed to determine the 
nature of the dose-response relationship between glycine and MMN in healthy 
controls.  
The empirical studies in this thesis were supported by two separately 
funded research schemes. Chapter four, examining MMN in cannabis users, was 
part of a project scheme investigating vulnerability markers in the association 
between cannabis use and schizophrenia. Chapters five and six, examining the 
effects of glycine in schizophrenia and in healthy controls, were part of a scheme 
investigating the efficacy of glycine as a therapeutic adjunct treatment in chronic 
schizophrenia patients. While these studies were part of a broader series of 
projects, they are complementary in clarifying the relationship between NMDAr 





7.2 Summary of Findings 
In chapter four, we examined duration and frequency MMN processing in a 
sample of forty-two regular cannabis users, compared to forty-four age- and 
gender-matched non-user controls. Within this sample, we then examined MMN 
in shorter- and longer-term cannabis users relative to their matched control 
counterparts. Frequency MMN amplitude was smaller in the overall sample of 
cannabis users, with this finding evident in both short- and long-term user groups. 
Smaller duration MMN amplitude was more pronounced in long-term users 
compared to controls and shorter-term users, and was associated with more 
prolonged and heavier cannabis use, particularly daily use, across the entire 
sample of regular users.  
In chapter five, we examined the effects of acute glycine administration 
(0.2g/kg) and chronic glycine treatment (increased to 0.6g/kg) as an adjunct to 
ongoing antipsychotic medication in chronic schizophrenia. In a sample of twenty-
two schizophrenia (or schizoaffective disorder) out-patients we compared the 
effects of glycine to that of placebo, utilising a randomised, double-blind, 
between-groups design. In this study, duration MMN amplitude at baseline was 
smaller in schizophrenia compared to age- and gender-matched controls. Acute 
administration of glycine increased duration MMN amplitude compared to 
placebo, while no between-group differences in MMN were found after 6-weeks 
of repeated glycine administration. Smaller duration MMN amplitude at baseline 
was associated with greater negative symptoms assessed using the Positive and 





negative symptoms following 6-weeks of adjunct glycine treatment (improvement 
defined as significantly reduced symptom scores from baseline to post-6-week 
treatment). No changes in negative symptoms were found following placebo.  
In chapter six, we examined the dose-response relationship between 
glycine and MMN in an independent sample of twenty healthy controls. In this 
study, we report a quadratic relationship between increasing glycine dose and 
change in MMN amplitude, providing evidence for an Inverted-U dose-response 
relationship following acute glycine administration. High-dose glycine (0.8g/kg) 
reduced MMN amplitude compared to low-dose (0.2g/kg) and medium-dose 
(0.4g/kg), while low-dose glycine increased MMN amplitude (at trend level) 
compared to placebo. Further, baseline MMN amplitude was linearly associated 
changes in MMN (from baseline to post-drug) following glycine administration, 
whereby larger baseline amplitudes were associated with reduced MMN and 
smaller baseline amplitudes were associated with increased MMN. 
 
7.3 General Discussion 
This thesis reports findings of smaller MMN amplitudes in regular cannabis users 
without psychiatric history, suggesting that regular use alters the sensitivity of 
MMN to index NMDAr functioning directly related to the pathophysiology of core 
schizophrenia phenotypes. Although the effects of regular cannabis use were not 
examined in schizophrenia patients, chapter four aimed to determine the nature 
of the relationship between regular cannabis exposure and MMN in otherwise 





use in altering endocannabinoid-mediated regulation of NMDAr excitability. 
Smaller MMN amplitudes in regular cannabis users (chapter four) support 
previous studies reporting cannabinoid type-I (CB1) receptor-mediated inhibition 
of NMDArs [156-158]. These findings suggest that prolonged cannabis use disrupts 
CB1-NMDAr regulatory mechanisms, thereby reducing NMDAr activation in 
cortical and subcortical networks important for MMN generation. 
In terms of clarifying the nature of the relationship between cannabis use 
and MMN, this thesis replicated previous findings of smaller frequency MMN 
amplitude [237] in a larger sample of heavier (average of 15.6 versus 8.8 joints per 
week) and more protracted (average 9.6 versus 3.0 years of regular use) cannabis 
users. Roser and colleagues [237] reported smaller frequency MMN amplitude in 
a sub-group of heavier and longer-term users, and a linear association between 
smaller frequency MMN amplitude and longer durations of cannabis use. Contrary 
to these findings, we did not report any relationship between frequency MMN and 
the duration or quantity of cannabis use. Instead, the development of frequency 
MMN deficits may be a less sensitive index of cumulative exposure to cannabis in 
our sample of heavier and more protracted users. These findings support the view 
that heavy and prolonged cannabis use results in pathophysiological and 
functional brain changes similar to the robust pattern of smaller frequency MMN 
amplitudes reported in chronic schizophrenia patients [337].  
Findings of smaller frequency MMN amplitude in regular cannabis users in 
this thesis are based on a cross-sectional design and do not offer direct causal 





for example, that cannabis users in chapter four had reduced frequency MMN 
amplitudes prior to the onset of use and that the results instead reflect a 
vulnerability to use cannabis. There is yet to be a longitudinal investigation to 
determine whether cannabis users, without history of psychosis, transition from 
normal frequency MMN (relative to non-users) prior to the onset of use, to smaller 
MMN amplitudes following prolonged exposure to cannabis. However, this 
interpretation is less likely given that Roser and colleagues [237] report longer 
durations of cannabis exposure with smaller frequency MMN amplitudes, 
suggesting MMN deficits develop with ongoing use. Rather than smaller frequency 
MMN amplitude indexing a pre-onset vulnerability to use cannabis, it is more likely 
that findings in chapter four index the impairing effects of prolonged cannabis 
exposure on frequency MMN processing. 
 Smaller frequency MMN amplitudes may index increased gyrification of 
the tonotopic organisation of the auditory cortex (AC) following repeated 
exposure to exogenous cannabinoids. This view is supported by previous findings 
of abnormal gyrification and cortical thinning in cannabis users, who were of 
similar age and duration of regular cannabis use to participants in chapter four 
[306]. Frequency MMN deficits (and to a lesser extent, duration MMN) in chronic 
schizophrenia patients has shown to be correlated with grey matter loss in the 
auditory and frontal cortices [286]. These findings are consistent with a model of 
increased age-related fractional anisotropy [367], cognitive decline [24]  and 
altered synaptic plasticity [250-253], with increasing disease progression in 





cannabis users in this thesis may index the effects of repeated cannabis exposure 
in down-regulating CB1 receptors, resulting in NMDAr-mediated abnormal 
gyrification of the auditory cortex, similar to that reported in chronic 
schizophrenia (for example, see [286]).  
Smaller duration MMN amplitudes may index functional impairment that is 
more sensitive to the degree of cannabis exposure following prolonged periods of 
use. The pattern of smaller duration MMN amplitude in regular users in this thesis 
(chapter four) has since been replicated in a sample of tobacco-naïve regular 
cannabis users [240]. Exogenous cannabinoids disrupt experience-dependent 
alterations in neuronal excitation [322] and synaptic integration across brain 
regions [325], which are necessary for neuronal plasticity and deviance detection. 
In regular cannabis users, ongoing exposure may lead to NMDAr-mediated 
alterations in cortico-thalamo networks in non-leminiscal pathways of the 
auditory system, which are required for duration MMN processing [195, 210, 246, 
313]. Smaller duration MMN amplitudes in this thesis (chapter four) were found 
in the long-term user subgroup only, with smaller amplitudes being associated 
with longer periods of daily (and regular) use in the overall sample of regular 
cannabis users. These findings are consistent with patterns of smaller duration 
MMN amplitude being associated with increased duration and frequency of 
cannabis use in schizophrenia patients [215]. Further, they support the view that 
smaller MMN amplitudes in response to duration deviants is more profound 
following protracted and heavier patterns of cannabis use.  





four) is contrary to the pattern of findings reported in schizophrenia. In chapter 
four, smaller duration MMN amplitudes were associated with more protracted 
cannabis use, while smaller duration MMN amplitudes in schizophrenia are 
primarily found in individuals at risk for developing psychosis or early in the 
prodrome [247, 249, 284]. It is unlikely that smaller duration MMN amplitude in 
cannabis users in this thesis (chapter four) index a premorbid psychosis 
vulnerability, as users had no history of psychosis despite their protracted use, and 
instead are likely to represent a sample of cannabis users without existing 
vulnerability. Differences in the pattern of duration MMN between long-term 
cannabis users and schizophrenia suggest a common functional deficit with 
different underlying neuropathology. Smaller duration MMN amplitudes have 
been shown to index lower thalamic glutamate plus glutamine levels in the 
prodromal stages of the illness [53], while our finding of smaller duration MMN 
amplitude in chronic schizophrenia patients (chapter five) was associated with 
greater negative symptoms, which is also thought to be mediated by 
hypofunctional NMDArs [54]. Together, these findings suggest MMN is a sensitive 
index of NMDAr hypofunction throughout the course of illness and further 
clarification is required to determine differences in underlying mechanisms of 
reduced MMN amplitude (as an index of NMDAr function), as well as their relation 
to clinical symptoms, during different stages of the disorder.  
 Smaller duration MMN amplitude in long-term cannabis users (chapter 
four) was associated with increased psychotic-like symptoms while intoxicated, 





function leads to downstream effects in neurotransmitter pathways such as 
dopamine. These findings are consistent with the glutamatergic hypothesis 
outlining a preliminary NMDAr hypofunction which leads to excessive dopamine 
release in the mesolimbic pathway [53-55]. CB1 receptors have been show to 
mediate the inhibition of glutamate release at excitatory neurons in the ventral 
tegmental area [368]. Findings of acute intoxication symptoms in this thesis 
(chapter four) are consistent with previous reports of smaller duration MMN 
amplitude being associated with increased psychotic symptoms in non-clinical 
individuals [369] and NMDAr antagonist models that induce psychotic symptoms 
in individuals without psychiatric history [51, 56].  Although cannabis users in 
chapter four did not develop psychosis (discussed above), these findings suggest 
a common neurochemical mechanism for which long-term cannabis use might 
lead to schizophrenia-like changes in the brain, particularly those associated with 
conversion to psychosis [178, 248]. 
 In determining the neurochemistry associated with smaller MMN 
amplitudes in schizophrenia, findings in chapter five confirm that acute glycine 
administration increases MMN amplitude in chronic patients. This suggests that 
glycine crosses the blood-brain barrier to increase NMDAr neurotransmission and 
supports the view that NMDAr hypofunction underlies robust MMN deficits 
previously reported in schizophrenia [241]. The same low-dose glycine 
administered in healthy controls (chapter six) favoured a trend towards increased 
MMN amplitude, but this difference was not significant in the overall sample when 





some individuals in chapter six had no, or little, benefit from receiving glycine. 
Although these studies are not directly comparable, together they support the 
view that increasing synaptic glycine concentration is more beneficial in the 
context of remediation, whereby those with lower baseline NMDAr function 
(indexed by MMN), such as in schizophrenia, benefit from increased excitatory 
neurotransmission following glycine administration.   
MMN may be useful in stratifying neurobiological function as a predictor 
of treatment response. The reported linear associations between baseline and 
changes in MMN amplitude following low- and high-dose glycine (chapter six) are 
consistent with the view that baseline NMDAr function mediates the effect of 
glycine. Almost all participants in chapter six had reduced MMN amplitudes 
following high-dose glycine, while findings were mixed (increases versus 
decreases) following low-dose. It is possible this linear relationship indexes a dose-
dependent effect of glycine, mediated by baseline levels of NMDAr functioning 
prior to treatment administration. However, caution is required when interpreting 
this linear relationship due to potential bias towards the mean. It may be that 
individuals with more extreme MMN amplitude values at baseline regress towards 
the mean for post-glycine measurements, thereby biasing the change score. 
Further research is required to confirm the effects of baseline NMDAr function in 
mediating functional outcomes following neuronal target engagement of glycine.   
Findings in chapter six confirm the nature of the relationship between 
glycine and MMN is that of an Inverted-U dose-response curve. High-dose glycine 





efficacy of high-dose glycine to increase NMDAr neurotransmission in healthy 
controls. This pattern is consistent with previous studies reporting decreased 
cognitive performance [226, 365] and reduced NMDAr currents [342] at higher 
synaptic glycine concentrations. Impaired pre-pulse inhibition, which is thought to 
be mediated by dopaminergic function, has also been reported following higher 
doses of glycine in patients with chronic schizophrenia [225, 359]. Contrary to 
previous reports [225], high-dose glycine in chapter six did not reduce MMN 
compared to placebo, suggesting that the high-dose condition did not ‘impair’ 
MMN generation in this study, but did reduced NMDAr function (indexed by 
smaller MMN amplitudes) when compared to low- and medium-doses. Further 
clarification of the functional significance of smaller MMN amplitude following 
higher (compared to low and medium) doses of glycine is needed in order to 
inform the potential risks of exceeding optimal synaptic glycine concentrations 
within a therapeutic context.  
Previous reports on the efficacy of increasing synaptic glycine 
concentration in schizophrenia have been inconsistent, with supporting evidence 
coming primarily from smaller independent trials [117, 122, 123] and mixed 
findings reported in recent Phase-II versus Phase-III clinical trials [128]. Since the 
publication of chapter five, two phase-III multi-centre trials of bitopertin were 
reported in a cumulative sample of 1199 schizophrenia patients [370]. Following 
24-weeks of treatment, bitopertin improved negative symptoms but did not show 
superior efficacy when compared to placebo. Contrary to these findings, glycine 





need for continued investigation into the conditions for optimal treatment 
efficacy. The sample of schizophrenia outpatients in chapter five were relatively 
low on positive symptoms compared to previous studies [128] and may index a 
more homogenous sample in relation to symptom profiles, particularly compared 
to larger trials. Inconsistencies across studies suggest NMDAr-mediated 
treatments may be beneficial in a subgroup of patients; however, categorising 
patients based on broad diagnostic features does not appear to adequately 
dissociate individuals who may benefit from increasing synaptic glycine 
concentrations. Further to this, Beck and colleagues [2] raise concerns of 
secondary negative symptoms inflating a placebo effect following NMDAr-
mediated treatments, particularly in chronic patients. Utilising a placebo and 
treatment-as-usual or waitlist group may help to further clarify the efficacy of 
NMDAr-mediated treatments in schizophrenia.   
Clinical findings in schizophrenia patients in this thesis (chapter five) report 
improved PANSS-Total, PANSS-Negative and PANSS-General symptoms, and 
favoured a trend towards improved depressive symptoms on the Calgary 
Depression Rating Scale (CDRS) following 6-weeks of glycine treatment. These 
findings support previous studies reporting improved symptoms following glycine 
[115-117, 121-123], D-Serine [118, 119] and NAC [120] in schizophrenia. While a 
full dissociation between primary and secondary negative symptoms is not 
feasible in this study design, scores on the CDRS and PANSS-General symptom 
scales were not associated with baseline or changes in MMN amplitude following 





of primary and secondary negative symptoms within a model of NMDAr 
hypofunction, but confirmatory research is needed to verify this dissociation. 
Following glycine treatment, there were no changes in functional impairment as 
assessed by the Work and Social Adjustment Scale, suggesting that changes in 
negative symptoms were not secondary to change in social functioning in this 
thesis. It may be that longer trials of NMDAr agents are required to facilitate more 
gross functional changes that are secondary to negative symptom improvement. 
The current findings support the need to investigate the nature of more global 
improvements in schizophrenia following increased glutamatergic function. 
In determining the relationship between MMN and clinical symptoms in 
schizophrenia in this thesis, smaller baseline MMN amplitude was found to be 
associated with greater severity in negative symptoms (chapter five). MMN has 
previously been associated with illness duration and premorbid, cognitive and 
psychosocial functioning [243, 284, 371], and in some studies with improved 
clinical symptoms [257, 339]. This finding is in line with the glutamatergic 
hypothesis and pathophysiological model of NMDAr hypofunction [53-55] 
involved in the generation of negative symptoms. In further support of this view, 
baseline duration MMN amplitudes predicted (at trend level) the degree of 
improved negative symptoms following 6-weeks of adjunct glycine treatment 
(chapter six).  Together, these findings support the use of MMN as an index of 
NMDAr deficit severity related to the pathophysiology of negative symptoms and 
suggest the need to stratify patients based on neurobiological dysfunction in order 





Findings of an Inverted-U relationship between glycine dose and MMN 
(chapter six) suggest there may be an optimal window for clinical benefits 
following NMDAr-mediated treatments. The state of NMDAr hypofunction [54] 
and reduced synaptic glycine concentrations [357] in schizophrenia may allow 
greater margin for increasing synaptic concentrations, before reaching saturation. 
This view suggests that the optimal dose to increase NMDAr function is higher in 
schizophrenia compared to controls. However, given the heterogeneity of NMDAr 
function within schizophrenia, these findings also suggest that higher doses may 
lead to more-varied treatment outcomes; higher doses may be beneficial in 
restoring NMDAr hypofunction in patients with low NMDAr neurotransmission, 
while the same dose administered in patients with relatively normal NMDAr 
functioning may lead to saturation of glycine at the synapse. If this is the case, only 
a subset of patients would be expected to benefit from higher doses of NMDAr-
mediated treatments. This view is further supported by findings of smaller 
duration MMN amplitudes predicting greater improvements in negative 
symptoms in schizophrenia patients (chapter five), whereby those with smaller 
MMN amplitudes experienced greater clinical benefits in negative symptoms 
following glycine treatment.   
MMN appeared sensitive to alterations in NMDAr function following acute 
glycine administration in schizophrenia (chapter five) and healthy controls 
(chapter six) in this thesis, however no differences in MMN were found following 
6-weeks of glycine treatment. This finding suggests that the efficacy of glycine to 





auditory cortical networks involved in MMN generation, as was inferred from 
findings in regular cannabis users in chapter five. An alternative explanation is that 
changes in duration MMN amplitude are a more sensitive index to state changes 
in NMDAr function, while improved clinical symptoms index the cumulative 
effects of glycine. It is noteworthy that glycine was not administered on the day of 
6-week follow-up testing in this thesis. It is possible that although acute glycine 
administration altered NMDAr function, repeated administration of adjunct 
glycine treatment may not lead to long-term plasticity changes over this time 
period. If so, this would mean that the therapeutic benefits reported in chapter 
five are due to cumulative exposure or possibly secondary effects on other 
neurochemical systems, rather than long-term changes to the NMDAr system 
itself. Consistent with this interpretation, altered duration MMN processing was 
associated with more prolonged and heavier periods of cannabis use in chapter 
five, whereby group differences in duration MMN amplitude were reported for 
the long-term user group only. 
 
7.4 Limitations and Future Direction 
Progressive decline in MMN amplitude, particularly in earlier stages of cannabis 
use, may overlap with models of advanced age-related decline reported in 
schizophrenia (for example, see [250]). Findings in regular cannabis users in this 
thesis are based on a cross-section design and are limited in offering direct causal 
evidence between repeated cannabis exposure and reduced MMN amplitude. 





biological mechanisms of repeated exposure to exogenous cannabinoids on 
progressive structural alterations contributing to MMN deficits reported in regular 
cannabis users. Given emerging evidence that increased cannabis dependence 
severity is associated with dopaminergic dysregulation [372] in neuronal pathways 
implicated in the pathophysiology of schizophrenia, future studies could control 
for changing severity of cannabis dependence. These findings may inform 
underlying mechanisms of positive and negative symptoms, and similarities in 
NMDAr-mediated structural and functional alterations between schizophrenia 
and regular cannabis users. 
 The concentrations of exogenous cannabinoids in cannabis plant matter 
used by participants in this thesis were not measured or controlled. Smaller MMN 
amplitudes in regular cannabis users (chapter four) suggest an ‘impairing’ effect 
of cannabis on NMDAr function in otherwise healthy individuals. Increasing the 
concentration of CBD in cannabis plant matter may reduce these ‘impairing’ 
effects. The purported therapeutic benefits of CBD for schizophrenia may increase 
NMDAr function in patients, as was demonstrated in chapter five following low-
dose glycine (indexed by changed in MMN). It was beyond the scope of the current 
thesis to examine the therapeutic efficacy of cannabis containing higher 
concentrations of CBD. Therefore, the direction of cannabis effects reported here 
should be interpreted with caution, particularly within the context of CBD as an 
alternative treatment for psychotic-related disorders. 
This thesis (chapter five) failed to replicate smaller frequency MMN 





generalise the effects of glycine across a broader framework of MMN deviance 
detection. Changes in experience-dependent plasticity has been demonstrated for 
frequency discrimination [350], whereby reorganisation of neuronal populations 
increase sensitivity to relevant stimuli and generate additional neuronal responses 
to trained frequencies. The malleability of this structural organisation is likely 
susceptible to pharmacological modulation, as was inferred from findings in 
regular cannabis users in chapter four. Future studies should investigate the 
effects of NMDAr-mediated treatments on frequency MMN processing, as it may 
be a more sensitive index (compared to duration MMN) of the cumulative effects 
following increased NMDAr function. Such findings may inform the differential 
patterns of each MMN deviant type throughout the chronicity of schizophrenia 
and the differential patterns of frequency versus duration MMN processing which 
were observed following regular cannabis use in this thesis. 
The low number of positive symptoms endorsed by schizophrenia 
outpatients in chapter five may not adequately index the potential therapeutic 
benefits of increasing synaptic glycine concentrations in treating this symptom 
domain. Research is required to map narrowly defined symptoms within 
schizophrenia. Determining the relationship between MMN as a marker of NMDAr 
function and its relationship with narrowly defined symptoms, particularly 
negative symptom sub-domains, may inform the transdiagnostic utility of MMN 
to index treatment-specific targets, rather than relying on broader diagnostic 
categorisation (which may be too broad to be relevant). Neurocomputational 





their primary and secondary nature, and facilitate greater accuracy in guiding early 
treatment interventions.  
Evidence of an Inverted-U dose-response relationship between glycine and 
MMN amplitude in this thesis is based on single-dose administration. The effects 
of long-term repeated dosing of glycine is unclear and may alter the efficacy of 
glycine to increase NMDAr function following repeated administration. It would 
thus be important to clarify whether the acute Inverted-U dose-response 
relationship between glycine and MMN remains when administered repeatedly in 
a model of treatment efficacy. Further, the nature of the dose-response 
relationship between glycine and MMN in this thesis was not directly examined in 
schizophrenia. It is unclear whether the Inverted-U curve is present in 
schizophrenia patients, or whether there is a linear increase in MMN amplitude 
following increased glycine dose. Replicating the nature of the Inverted-U 
relationship in schizophrenia may better inform optimal treatment doses to 
increase NMDAr hypofunction in schizophrenia and further inform the 
heterogeneity of treatment outcomes at higher glycine doses.  
A methodological limitation in our examination of the glycine dose-
response effect in healthy controls (chapter six), is comparability to previous 
findings [225]. Our use of a change variable to examine the effects of glycine 
(change from baseline to post-drug administration) aimed to control for potential 
differences in baseline MMN amplitude across treatment sessions. Following high-
dose glycine, we report reduced MMN amplitudes in individuals with higher 





effect in the low baseline group, while the longer testing period, including baseline 
and post-drug measures, may have created a regression towards the mean, 
reducing the sensitivity of our measure to index glycine-mediated changes in 
MMN. Future studies should investigate the significance of reduced MMN relative 
to other cognitive performance measures sensitive to functional outcomes in 
schizophrenia.  
While this thesis informs the nature of the relationship between NMDAr 
function and MMN amplitude, these findings are limited in informing the 
mechanisms underlying changes in MMN generation. Utilising MRI brain structural 
analysis to support current source density mapping may be a useful way to 
examine the effects of pharmacological intervention and inform the mechanisms 
for different deviant types. A combined spectral decomposition analysis of the 
MMN waveform may inform the independent contributions of cortico-cortico and 
cortico-thalamic networks in altering MMN generation, particularly following 
increased synaptic glycine concentration. These methods may aid further 
understanding of the independent and overlapping pathways involved in 
frequency versus duration MMN processing, and inform differential findings 
reported throughout the chronicity of schizophrenia and following prolonged 
periods of cannabis use, as well as their sensitivity in predicting treatment 
outcomes. 
A limitation of glycine and other NMDAr agonists, such as D-serine, is the 
variability they introduce from metabolic processes and the large doses required 





this thesis following administration of GT1-RIs, such as bitopertin and sarcosine. 
These treatments increase synaptic glycine concentrations by blocking the 
reuptake of glycine in the synapse. Determining whether GT1-RIs have a similar 
effect to that of glycine will provide important information as to the mechanism 
of their effect. It may be, for example, that GT1-RIs require sufficient endogenous 
glycine to be efficacious, and that lower endogenous glycine levels may limit their 
ability to improve NMDAr function. Such information would be important for 
tailoring effective treatments for the heterogeneity present in schizophrenia.  
While this thesis aimed to determine the nature of the relationship 
between MMN and NMDAr function, it is limited in informing the mechanisms of 
change in neuronal functioning. This thesis concludes that altering NMDAr 
function may result in different neuronal functional outcomes and that such 
variabilities in neuronal response is likely involved in the heterogeneity of clinical 
treatment efficacy in schizophrenia following NMDAr-mediated treatments. 
However, the findings used to infer this relationship, including regular cannabis 
use and the dose-response effects of glycine, were not directly examined in 
schizophrenia patients. The nature of the relationship between MMN, regular 
cannabis use and glycine dose-dependence may differ within the context of 
NMDAr hypofunction in schizophrenia patients. Therefore, further studies are 
required to confirm the stability of these MMN findings in schizophrenia, in order 
to understand their implications for indexing neuronal target engagement and 






7.5 Conclusion  
This thesis demonstrates that MMN is a sensitive biomarker to index the 
neurobiological state of NMDAr function. Chapter four provides indirect evidence 
of endocannabinoid-mediated alterations of NMDArs in auditory cortical 
networks important for MMN generation. Acute administration of glycine in 
chapter five increased MMN in schizophrenia patients and the same pattern was 
observed (at trend level) in chapter six following low-dose glycine administered in 
healthy controls. An Inverted-U dose-response relationship between glycine and 
MMN suggests there is an optimal therapeutic window for glycine to increase 
NMDAr function, beyond which treatment efficacy is reduced. Together, these 
findings indicate that changes in MMN index alterations in NMDAr function, which 
may arise from pre or post-synaptic mechanisms. Further, they support the utility 
of MMN to index changes in NMDAr excitability following neuronal target 
engagement of NMDAr-mediated treatments. Indexing change in NMDAr function 
following treatment may identify subgroups of patients who will (and won’t) 
benefit from increasing synaptic glycine concentrations. 
The efficacy of glycine to increase NMDAr function in this thesis appeared 
greater in the context of remediation, whereby increasing synaptic glycine 
concentration improved MMN in models of NMDAr hypofunction. Smaller 
duration and frequency MMN amplitudes were associated with intoxicated 
psychotic-like symptoms in long-term regular cannabis users, while smaller 
duration MMN amplitude in schizophrenia was associated with greater severity of 





following glycine treatment. These findings suggest that MMN is a useful index to 
stratify core phenotypes based on biological dysfunction, rather than broad 
diagnostic criteria. It would be useful for future studies to replicate findings of an 
Inverted-U dose-response relationship for MMN following administration of 
glycine-reuptake inhibitors, such as bitopertin. Clarifying this relationship would 
assist in tailoring effective treatment and further inform the heterogeneity of 
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